| Literature DB >> 35096168 |
Tengku Siti Hajar Haryuna1, Dyah Fauziah2, Sari Anggraini1, M Pahala Hanafi Harahap1, Juliandi Harahap3.
Abstract
Introduction Aminoglycoside, as an antimicrobial medication, also has side-effects on the inner ears, bringing about hearing disorders. Curcumin has been proven to be a strong scavenger against various reactive oxygen species (ROS), and the increase in ROS production is considered to play an important role in the process of hearing disorder. Objective To prove that curcumin is an effective antioxidant to prevent cochlear damage based on malondialdehyde (MDA) expression. Methods The present research used 32 Rattus norvegicus , of the Wistar lineage, randomly divided into 8 groups: negative control, ototoxic control (a single dose of 40 mg/ml of gentamicin via intratympanic injection), 2 groups submitted to ototoxic control + curcumin treatment (100 mg/kg, 200 mg/kg), 2 groups who iunderwent ototoxic control + curcumin treatment for 7 days, and two groups submitted to curcumin treatment as prevention for 3 days + ototoxic induction. Results The results showed that the lowest dosage of curcumin (100 mg/kg) could decrease MDA expression on the cochlear fibroblastic wall of the ototoxic model; however using greater doses of curcumin (200 mg/kg) for 7 days would provide a better effect. Curcumin could also significantly decrease MDA expression when it was administered during the preototoxic exposure. Conclusion Curcumin can be used as a therapy for ototoxic prevention based on the decrease in MDA expression. Fundação Otorrinolaringologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: cochlear fibroblast; curcumin; gentamicin; malondialdehyde; ototoxicity; reactive oxygen species
Year: 2021 PMID: 35096168 PMCID: PMC8789483 DOI: 10.1055/s-0040-1722161
Source DB: PubMed Journal: Int Arch Otorhinolaryngol ISSN: 1809-4864
Setup of the ototoxic model group
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | Group 7 | Group 8 |
|---|---|---|---|---|---|---|---|
| Control | gentamycin 40 mg/ml | gentamycin 40 mg/ml | gentamycin 40 mg/ml | gentamycin 40 mg/ml | gentamycin 40 mg/ml |
Days 1–3:
|
Days 1–3:
|
| ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ | ↓ |
| Termination in 18 hours | Termination in 18 hours | Termination in day 9 | Termination in 18 hours | ||||
Fig. 1Supporting tissues and cochlea lateral walls with immunohistochemical (IHC) pigmentation (magnification: 10x). The directional arrow indicates the lateral walls.
Fig. 2Malondialdehyde (MDA) expression in each group (magnification: 40x): ( A ) group 1; ( B ) group 2; ( C ) group 3; ( D ) group 4; ( E ) group 5; ( F ) group 6; ( G ) group 7; and ( H ) group 8. The directional arrow indicates the brownish color that characterizes MDA expression in the cochlear fibroblast.
Fig. 3The mean value of MDA expression in the fibroblast of cochlear lateral walls in an ototoxic rat model during the IHC examination.
Analysis of variance for malondialdehyde expression
| Group | Group | Standard deviation |
|
|---|---|---|---|
| Group 1 | 2 | 5.000* ± 1.070 | .000* |
| 3 | 4.250* ± 1.070 | .001* | |
| 4 | 3.500* ± 1.070 | .003* | |
| 5 | 1.750 ± 1.070 | .115 | |
| 6 | .250 ± 1.070 | .817 | |
| 7 | .000 ± 1.070 | 1.000 | |
| 8 | .25 ± 1.070 | .817 | |
| Group 2 | 3 | .750 ± 1.070 | .490 |
| 4 | 1.500 ± 1.070 | .174 | |
| 5 | 3.250* ± 1.070 | .006* | |
| 6 | 4.750* ± 1.070 | .000* | |
| 7 | 5.000* ± 1.070 | .000* | |
| 8 | 5.250* ± 1.070 | .000* | |
| Group 3 | 4 | .750 ± 1.070 | .490 |
| 5 | 1.750 ± 1.070 | .028* | |
| 6 | 3.250* ± 1.070 | .001* | |
| 7 | 4.250* ± 1.070 | .001* | |
| 8 | 4.500* ± 1.070 | .000* | |
| Group 4 | 5 | 1.750 ± 1.070 | .115 |
| 6 | 3.250* ± 1.070 | .006* | |
| 7 | 3.500* ± 1.070 | .003* | |
| 8 | 5.750* ± 1.070 | .002* | |
| Group 5 | 6 | 1.500 ± 1.070 | .174 |
| 7 | 1.750 ± 1.070 | .115 | |
| 8 | 2.000 ± 1.070 | .074 | |
| Group 6 | 7 | .250 ± 1.070 | .817 |
| 8 | .500 ± 1.070 | .645 | |
| Group 7 | 8 | .250 ± 1.070 | .817 |
Note: * p ≤ 0.05: statistically significant difference.